CN106771185A - A kind of nasopharyngeal carcinoma circulating tumor cell detection kit - Google Patents
A kind of nasopharyngeal carcinoma circulating tumor cell detection kit Download PDFInfo
- Publication number
- CN106771185A CN106771185A CN201611103862.2A CN201611103862A CN106771185A CN 106771185 A CN106771185 A CN 106771185A CN 201611103862 A CN201611103862 A CN 201611103862A CN 106771185 A CN106771185 A CN 106771185A
- Authority
- CN
- China
- Prior art keywords
- nasopharyngeal carcinoma
- quantum dot
- circulating tumor
- tumor cell
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/14—Disorders of ear, nose or throat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a kind of nasopharyngeal carcinoma circulating tumor cell detection kit, it is made up of human peripheral leucocytes removal part and immunofluorescence in situ hybridization identification part, wherein human peripheral leucocytes removal part includes dilution buffer, erythrocyte cracked liquid, density gradient centrifugation medium, cell fixer A and immunomagnetic beads, and wherein erythrocyte cracked liquid is mixed by ammonium chloride, sodium acid carbonate and EDETATE SODIUM solution.Described immunofluorescence in situ hybridization identification part includes buffer solution, hybridizes fixer B, the CEP8 probes of biotin labeling, the CD45 antibody of red quantum dot mark, the quantum dot-labeled Streptavidin of green, mountant and bovine serum albumin(BSA) powder.The kit combines immune magnetic enrichment isolation technics, fluorescence in situ hybridization technique, Immunofluorescence technology, nasopharyngeal carcinoma circulating tumor cell counting technology, can accurately determine nasopharyngeal carcinoma circulating tumor cell number in sample.
Description
Technical field
The invention provides a kind of detection kit of nasopharyngeal carcinoma circulating tumor cell, belong to nasopharyngeal carcinoma circulating tumor cell
Detection field.
Background technology
Circulating tumor cell (Circulating Tumor Cells, CTCs) refers to the tumour cell entered into blood.This
Partial tumors cell is participated in the middle of blood circulation, and as sanguimotor direction can be migrated to linked groups or device
Official, develops into tumor focus under suitable conditions.CTCs main sources are divided into two aspects：One to come off, i.e., by primary tumor or
MET splits away off penetrate blood wall and enters into blood.Two is stage entrance earlier, i.e., form image in not yet propagation
When learning visible tumor focus tissue, entered into blood in advance in the form of cancerous tumor cell, therefore theoretically, CTCs's
Occur will be earlier than iconography to tumor entity discovery.
The common inspection method of nasopharyngeal carcinoma has：Magnetic resonant imaging examination, CT examination, pharyngorhinoscopy, X-ray examination, blood
It is clear to learn diagnosis etc..Common being mainly based on serodiagnosis is disliked according to Epstein-Barr virus antibody level in patients with nasopharyngeal carcinoma with other
There is notable difference between tumor patient and Healthy People in property.
Pharynx nasalis anatomical position is hidden, and nasopharyngeal carcinoma early symptom is not true to type, clinically easy delay diagnosis, should especially improve
It is vigilant.And the treatment method of nasopharyngeal carcinoma is mainly based on chemicotherapy, Nasopharyngeal Carcinoma Patients circulating tumor cell is detected and monitored
Quantity can point out early diagnosis, and carry out the assessment of chemicotherapy curative effect.
Detected using people's periphery whole blood, in phase morning, noon and afternoon Nasopharyngeal Carcinoma Patients blood, simply by the presence of entering blood circulation
Nasopharyngeal carcinoma tumor cell, can be detected.Because CTC is few in the quantity of peripheral blood, generally need to be in about 100,000,000 leucocytes
With only several tumour cells are found in 50,000,000,000 red blood cells, therefore in order to improve the recall rate of CTC, generally must be in detection
Before carry out CTC enrichments.The enrichment method of current CTC by its principle be broadly divided into concentration method based on antigen-antibody reaction principle and
Enrichment method based on cellular morphology.And the detection method of CTC is numerous, two major classes can be divided into according to Cleaning Principle：Cytometer
Number method and nucleic acid detection method, the former is mainly including various immunocytochemical techniques, flow cytometry, immunofluorescence technique etc.；
The latter is mainly including polymerase chain reaction, RT-polymerase chain reaction and its various improved technologies etc..Current detection side
Generally existing has following defect in method：Because the leukocyte removal efficiency in peripheral blood is not high, leucocyte can be right as karyocyte
The enrichment of tumour cell is interfered.Additionally, haematogenous abnormal cell also can (circulating tumor be thin to non-haematogenous abnormal cell
Born of the same parents) screening interfere.Additionally, at present mostly using the method capture circulating tumor cell of positive sorting, using magnetic bead surfaces
Coupling has specific antibody (such as Epcam, CK19) to capture tumour cell, and the cell surface that the method is obtained carries magnetic bead, leads
Cause cytoactive reduction.And due to the relation of mark, cause the tumor cell enrichment rate of recovery relatively low.
The content of the invention
The present invention solves deficiency of the prior art, there is provided a kind of nasopharyngeal carcinoma circulating tumor cell detection kit,
The kit combines immune magnetic enrichment isolation technics, fluorescence in situ hybridization technique, Immunofluorescence technology, nasopharyngeal carcinoma and follows
Ring tumour cell counting technology, can accurately determine nasopharyngeal carcinoma circulating tumor cell number in sample.
Realize technical scheme that above-mentioned purpose of the present invention used for：
A kind of nasopharyngeal carcinoma circulating tumor cell detection kit, it is former by human peripheral leucocytes removal part and immunofluorescence
Position hybridization identification part constitutes, and wherein human peripheral leucocytes removal part includes dilution buffer, erythrocyte cracked liquid, density
Gradient centrifugation medium, cell fixer A and immunomagnetic beads, wherein erythrocyte cracked liquid by ammonium chloride, sodium acid carbonate and
EDETATE SODIUM solution is mixed, the magnetic bead of the antibody of the immunomagnetic beads anti-human LCA that has been covalent coupling,
The antibody is CD45, and immunomagnetic beads particle diameter used is 0.2~1.5 μm；Cell fixer A functional components are alcohols；
Described immunofluorescence in situ hybridization identification part includes buffer solution, hybridizes fixer B, the CEP8 of biotin labeling
Probe, the CD45 antibody of red quantum dot mark, the quantum dot-labeled Streptavidin of green, mountant and bovine serum albumin
White powder end；The hybridization fixer B functional components are paraformaldehyde, and the CEP8 probes can be by the side of FISH
Method carries out probe mark to tumour cell, and the CD45 antibody of the red quantum dot mark is dyeed and it to remaining leucocyte
Launch wavelength is 585nm~625nm, and the quantum dot-labeled Streptavidin of green can be combined so as to right with CEP8 probes
DNA fragmentation is marked, and its launch wavelength is 525nm~545nm, and the mountant contains what can be combined with DNA strengths
Fluorescent dye DAPI.
The pH value of described erythrocyte cracked liquid is 7.0~8.0, and wherein the concentration of ammonium chloride is 0.5~2M, sodium acid carbonate
Concentration is 10~200mM, and the concentration of EDETATE SODIUM is 1~10mM.
The CEP8 probes of described biotin labeling are purchased from branch and subsidiaries of Abbott Laboratories of the U.S..
The launch wavelength of the CD45 antibody of red quantum dot mark is 605nm, the quantum dot-labeled Streptavidin of green
Launch wavelength be 525nm, with albumen be attached quantum dot by the way of covalent coupling by both of which.
The density of described density gradient centrifugation medium is 1.02~1.5g/cm3, its active ingredient is sucrose, and sucrose
Mass concentration be 5%~60%.
Compared with prior art, the present invention has advantages below：The present invention is obtained using the method for the negative enrichment of negative sorting
Activity of tumor cells it is high, the tumor cell enrichment rate of recovery be more than 80%.The fluorescence quantum that kit is used is used as non-blood source
Property gene unconventionality type cell marker for determination thing, it is high to be mainly characterized by fluorescent brightness, stable performance, is difficult bleaching, it is easy to observe.
, using the negative method being enriched with, resulting tumor cell surface is complete, and activity is high, more conveniently carries out for the present invention
Follow-up cultivation and molecular marker analyte detection.
The present invention substantially increases circulating tumor thin using blood plasma, erythrocyte splitting technology, density gradient centrifugation is removed
The accumulation rate of born of the same parents, leukocyte removal efficiency is more than 99.99%.
The present invention is using FISH and Immunofluorescence technology to the circulating tumor cell that is enriched to
Identified, No. 8 chromosome probes are marked to DNA of tumor cell sequence, as a result can show triploid, tetraploid, many times
Body signal.It is not only restricted to the expression of epithelium mark using the method for FISH, improves the sensitiveness of detection and special
Property.The CD45 antibody of red quantum dot mark is dyeed to leukocyte surface, is made a distinction with tumour cell.Counted to get
Tumour it is carefully accurate.
CTC beneficiation technologies of the present invention use the negative concentration method based on immune magnetic principle, by using specific Dan Ke
The grand coated immune magnetic particle of antibody (CD45) can remove in blood more than 99.99% leucocyte, farthest reduce the back of the body
The interference of scape karyocyte, so as to reach the purpose of enriched tumor cell.Because not relying on the expression of TCSA,
CTC enrichment methods of the present invention possess certain versatility in each epithelial origin solid tumor, can reach tumour cell higher and return
Yield.To exclude the interference of haematogenous abnormal cell, original creation technology of the present invention：By from specific probe by FISH with it is immune
Cytochemical Technique is combined, and using fluorescence quantum as label, quickly filters out non-haematogenous gene unconventionality type cell
(tumour cell).
Brief description of the drawings
The overhaul flow chart of the nasopharyngeal carcinoma circulating tumor cell detection kit that Fig. 1 is provided for the present invention；
Fig. 2 is the clinical samples detection data analysis chart in the embodiment of the present invention.
Specific embodiment
Detailed specific description is done to the present invention with reference to specific embodiment, but protection scope of the present invention not office
It is limited to following examples.
Nasopharyngeal carcinoma circulating tumor cell detection kit provided by the present invention by human peripheral leucocytes removal part and
Immunofluorescence in situ hybridization identification part constitutes, and wherein human peripheral leucocytes removal part includes dilution buffer, red blood cell
Lysate, density gradient centrifugation medium, cell fixer A and immunomagnetic beads, wherein erythrocyte cracked liquid is by ammonium chloride, carbonic acid
Hydrogen sodium and EDETATE SODIUM solution are mixed, the antibody of the immunomagnetic beads anti-human LCA that has been covalent coupling
Magnetic bead, the antibody be CD45, immunomagnetic beads particle diameter used be 0.2~1.5 μm.The pH value of described erythrocyte cracked liquid is
7.0~8.0, the wherein concentration of ammonium chloride is 0.5~2M, and sodium acid carbonate concentration is 10~200mM, and the concentration of EDETATE SODIUM is 1
~10mM.The density of described density gradient centrifugation medium is 1.02~1.5g/cm3, its active ingredient is sucrose, and sucrose
Mass concentration is 5%~60%.The cell fixer A main components are alcohols.
Described immunofluorescence in situ hybridization identification part includes buffer solution, hybridizes fixer B, the CEP8 of biotin labeling
Probe, the CD45 antibody of red quantum dot mark, the quantum dot-labeled Streptavidin of green, mountant and and cow's serum
Albumin powder, the CEP8 probes can carry out probe mark to tumour cell by the method for FISH, described
Biotin labeling CEP8 probes be purchased from branch and subsidiaries of Abbott Laboratories of the U.S..The hybridization fixer B is to before aging dehydration
Cell is fixed, and main component is paraformaldehyde.The CD45 antibody of the red quantum dot mark is carried out to remaining leucocyte
Dye and its launch wavelength is 585nm~625nm, the launch wavelength of the CD45 antibody of red quantum dot mark is in the present embodiment
605nm, the quantum dot-labeled Streptavidin of green can be combined so as to be marked to DNA fragmentation with CEP8 probes, and
Its launch wavelength is 525nm~545nm, and the launch wavelength of the quantum dot-labeled Streptavidin of the present embodiment Green is
525nm.The CD45 antibody of red quantum dot mark is with green quantum dot-labeled Streptavidin using the side of covalent coupling
With albumen be attached quantum dot by formula.The mountant contains the fluorescent dye DAPI that can be combined with DNA strengths.
Nasopharyngeal carcinoma circulating tumor cell detection kit provided by the present invention overhaul flow chart such as Fig. 1 institutes when in use
Show, specific step is as follows：
1st, blood plasma and red blood cell are removed：5~10min removals are centrifuged after buffer solution 450g~1000g is added in blood sample
Blood plasma, is subsequently adding 450g~1000g erythrocyte cracked liquids and 8-12min is rotated in shaking table, obtains white after 5~10min of centrifugation
Cell and tumour cell.
2nd, leucocyte removal：Immune magnetic particle is added in the leucocyte and tumour cell mixture that will obtain in horizontal shaker
Middle reaction, immune magnetic particle surface coupling has the antibody of anti-human LCA, magnetic particle specificity and leucocyte knot
Close, can be combined with sample 99.99% leucocyte, so as to reach the purpose of removal leucocyte.
3rd, density gradient centrifugation：The magnetic particle and tumour cell mixture that leucocyte will be captured gently be superimposed to from
In heart medium, by density gradient centrifugation, as a result can be divided into 4 layers, bottom is immune magnetic particle and leukocyte complexes, according to
Secondary is up centrifugation medium layer, tumor cells, buffer layer.Tumor cells are drawn according to purpose, may be remained immune
Magnetic particle, removes residual immunity magnetic particle by way of by magnetic frame, and the cell centrifugation for obtaining takes out bottom after bottom of the tube
Cell carries out smear.
4th, cell technique for fixing：Cell added cell fixer A after smear, in 25 DEG C~30 DEG C dryings 12~36 hours.
5th, hybridization in situ technique：After the cell after smear is completely dried, cell compartment is carried out using hybridization fixer B
Fixed, then aging, dewater treatment carries out in situ hybridization.Used probe is the CEP8 of biotin labeling, and hybridization instrument setting becomes
Degree warm in nature is 76 DEG C, and the time is 5min；Hybridization temperature is 37 DEG C, and the time is 1.5~3h.Hybridization is finished, and is taken out slide and is washed
Wash.
6th, Immunofluorescence technology：After the slide washing of in situ hybridization will have been completed, red quantum dot mark is prepared
The Streptavidin CD45 of note quantum dot-labeled with green is added to cell specimen dyeing liquor as immunofluorescence dyeing liquid
Area is washed in 37 DEG C of 1~3h of incubation after the completion of incubation, adds DAPI mountants to carry out mounting.
7th, tumour cell counting technology：The slide that in situ hybridization and Immunofluorescence test will have been completed is placed in fluorescence microscope
Under, burst of ultraviolel observation blueness DAPI signals, it may be determined that karyomorphism；Observation green CEP8 probe signals, it may be determined that cell
Hybridization signal point number in core；Observation red CD45 signals, determine leukocyte cell film staining conditions；It is final to determine that nucleus is
Monokaryon, probe signals point three and more than, the cell without CD45 staining signals is abnormal cell (tumour cell) and to count, whole
Slide is scanned, counts tumour cell number, tumour cell number as contained by the sample.
The present embodiment has found 103 for clinical samples are tested and analyzed, and has 27 healthy volunteers in 103 samples
(Healthy Controls), 34 pharynx nasalis benign lesion patients (Non-maniglant Disease) and 42 nasopharyngeal carcinoma
Patient, the circulating tumor cell detection data distribution of above clinical samples is provided by the present invention as shown in Fig. 2 as shown in Figure 2
The testing result of nasopharyngeal carcinoma circulating tumor cell detection kit is consistent with actual state.
Claims (5)
1. a kind of nasopharyngeal carcinoma circulating tumor cell detection kit, it is characterised in that by human peripheral leucocytes removal part and exempt from
Epidemic disease FISH identification part constitutes, and wherein human peripheral leucocytes removal part includes that dilution buffer, red blood cell are split
Solution liquid, density gradient centrifugation medium, cell fixer A and immunomagnetic beads, wherein erythrocyte cracked liquid is by ammonium chloride, bicarbonate
Sodium and EDETATE SODIUM solution are mixed, the antibody of the immunomagnetic beads anti-human LCA that has been covalent coupling
Magnetic bead, the antibody is CD45, and immunomagnetic beads particle diameter used is 0.2~1.5 μm；Cell fixer A functional components are alcohols；
Described immunofluorescence in situ hybridization identification part includes buffer solution, hybridizes fixer B, and the CEP8 of biotin labeling is visited
Pin, the CD45 antibody of red quantum dot mark, the quantum dot-labeled Streptavidin of green, mountant and bovine serum albumin(BSA)
Powder；The hybridization fixer B functional components are paraformaldehyde, and the CEP8 probes can be by the method for FISH
Probe mark is carried out to tumour cell, remaining leucocyte is dyeed the CD45 antibody of the red quantum dot mark and it is sent out
A length of 585nm~the 625nm of ejected wave, the quantum dot-labeled Streptavidin of green can be combined so as to DNA with CEP8 probes
Fragment is marked, and its launch wavelength is 525nm~545nm, and the mountant contains the fluorescence that can be combined with DNA strengths
Dyestuff DAPI.
2. nasopharyngeal carcinoma circulating tumor cell detection kit according to claim 1, it is characterised in that：Described red blood cell
The pH value of lysate is 7.0~8.0, and wherein the concentration of ammonium chloride is 0.5~2M, and sodium acid carbonate concentration is 10~200mM, EDTA
The concentration of disodium is 1~10mM.
3. nasopharyngeal carcinoma circulating tumor cell detection kit according to claim 1, it is characterised in that：Described biotin
The CEP8 probes of mark are purchased from branch and subsidiaries of Abbott Laboratories of the U.S..
4. nasopharyngeal carcinoma circulating tumor cell detection kit according to claim 1, it is characterised in that：Red quantum dot mark
The launch wavelength of the CD45 antibody of note is 605nm, and the launch wavelength of the quantum dot-labeled Streptavidin of green is 525nm, two
With albumen be attached quantum dot by the way of covalent coupling by person.
5. nasopharyngeal carcinoma circulating tumor cell detection kit according to claim 1, it is characterised in that：Described density level bands
The density for spending centrifugation medium is 1.02~1.5g/cm3, its active ingredient is sucrose, and sucrose mass concentration for 5%~
60%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611103862.2A CN106771185A (en) | 2016-12-05 | 2016-12-05 | A kind of nasopharyngeal carcinoma circulating tumor cell detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611103862.2A CN106771185A (en) | 2016-12-05 | 2016-12-05 | A kind of nasopharyngeal carcinoma circulating tumor cell detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106771185A true CN106771185A (en) | 2017-05-31 |
Family
ID=58874043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611103862.2A Pending CN106771185A (en) | 2016-12-05 | 2016-12-05 | A kind of nasopharyngeal carcinoma circulating tumor cell detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106771185A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107907399A (en) * | 2017-11-24 | 2018-04-13 | 遵义医学院 | A kind of preparation method for the mountant that can mark nucleus at the same time |
| CN109100511A (en) * | 2018-07-20 | 2018-12-28 | 四川大学 | Capture and the immune magnetic nano particle of release and preparation method thereof are visualized for circulating tumor cell |
| CN109439732A (en) * | 2018-12-25 | 2019-03-08 | 迈迪速能医学技术（天津）有限公司 | A kind of kit early sieved for three-dimensional noninvasive tumour |
| CN111024624A (en) * | 2019-12-20 | 2020-04-17 | 东南大学 | PARP-1 single particle detection method based on dark field scattering imaging |
| CN111351937A (en) * | 2018-12-20 | 2020-06-30 | 上海细胞治疗集团有限公司 | MMR protein expression deletion detection kit and detection method thereof |
| CN111471678A (en) * | 2020-04-29 | 2020-07-31 | 河南赛诺特生物技术有限公司 | Human chromosome 8 centromere probe and preparation method and kit thereof |
| CN114636820A (en) * | 2022-05-07 | 2022-06-17 | 珠海圣美生物诊断技术有限公司 | Kit and method for detecting circulating PD-L1 positive cells |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525669A (en) * | 2009-03-11 | 2009-09-09 | 中国人民解放军第三军医大学第一附属医院 | Nuclear acid probe marked with quantum-dots composite sphere and preparation method and application thereof |
| CN101587043A (en) * | 2008-05-20 | 2009-11-25 | 林平 | Integrated method for enriching and detecting rare cell in biological fluid sample |
| CN105087775A (en) * | 2015-07-24 | 2015-11-25 | 北京莱尔生物医药科技有限公司 | Method and related kit for detecting c-MET/CEP7 gene status based on rare cells |
| CN105606797A (en) * | 2016-01-15 | 2016-05-25 | 浙江博真生物科技有限公司 | Antibody composition and application of antibody composition in leukemia and lymphoma typing |
| CN105891165A (en) * | 2014-11-04 | 2016-08-24 | 郝淮杰 | Method and kit for separating rare cells from peripheral blood |
-
2016
- 2016-12-05 CN CN201611103862.2A patent/CN106771185A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101587043A (en) * | 2008-05-20 | 2009-11-25 | 林平 | Integrated method for enriching and detecting rare cell in biological fluid sample |
| CN101525669A (en) * | 2009-03-11 | 2009-09-09 | 中国人民解放军第三军医大学第一附属医院 | Nuclear acid probe marked with quantum-dots composite sphere and preparation method and application thereof |
| CN105891165A (en) * | 2014-11-04 | 2016-08-24 | 郝淮杰 | Method and kit for separating rare cells from peripheral blood |
| CN105087775A (en) * | 2015-07-24 | 2015-11-25 | 北京莱尔生物医药科技有限公司 | Method and related kit for detecting c-MET/CEP7 gene status based on rare cells |
| CN105606797A (en) * | 2016-01-15 | 2016-05-25 | 浙江博真生物科技有限公司 | Antibody composition and application of antibody composition in leukemia and lymphoma typing |
Non-Patent Citations (3)
| Title |
|---|
| FENG LI ET AL: "circulating tumor cells in the blood of poorly differentiated nasal squamous cell carcinoma patients: correlation with treatment response", 《ACTA OTO-LARYNGOLOGICA》 * |
| 伍勇 等: "循环肿瘤细胞与鼻咽癌临床病理参数的相关性研究", 《中国医药科学》 * |
| 余家会: "《纳米生物医药》", 31 December 2011 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107907399A (en) * | 2017-11-24 | 2018-04-13 | 遵义医学院 | A kind of preparation method for the mountant that can mark nucleus at the same time |
| CN109100511A (en) * | 2018-07-20 | 2018-12-28 | 四川大学 | Capture and the immune magnetic nano particle of release and preparation method thereof are visualized for circulating tumor cell |
| CN109100511B (en) * | 2018-07-20 | 2019-09-24 | 四川大学 | Capture and the immune magnetic nano particle of release and preparation method thereof are visualized for circulating tumor cell |
| CN111351937A (en) * | 2018-12-20 | 2020-06-30 | 上海细胞治疗集团有限公司 | MMR protein expression deletion detection kit and detection method thereof |
| CN109439732A (en) * | 2018-12-25 | 2019-03-08 | 迈迪速能医学技术（天津）有限公司 | A kind of kit early sieved for three-dimensional noninvasive tumour |
| CN109439732B (en) * | 2018-12-25 | 2024-04-12 | 迈迪速能医学技术（天津）有限公司 | Kit for three-dimensional noninvasive tumor early screening |
| CN111024624A (en) * | 2019-12-20 | 2020-04-17 | 东南大学 | PARP-1 single particle detection method based on dark field scattering imaging |
| CN111471678A (en) * | 2020-04-29 | 2020-07-31 | 河南赛诺特生物技术有限公司 | Human chromosome 8 centromere probe and preparation method and kit thereof |
| CN114636820A (en) * | 2022-05-07 | 2022-06-17 | 珠海圣美生物诊断技术有限公司 | Kit and method for detecting circulating PD-L1 positive cells |
| CN114636820B (en) * | 2022-05-07 | 2022-10-21 | 珠海圣美生物诊断技术有限公司 | Kit and method for detecting circulating PD-L1 positive cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106771185A (en) | A kind of nasopharyngeal carcinoma circulating tumor cell detection kit | |
| CN104007257B (en) | Method for detecting non-humoral rare karyotes, and kit thereof | |
| US20110195413A1 (en) | Integrated Method for Enriching and Detecting Rare Cells from Biological Body Fluid Sample | |
| CN105954246B (en) | Method and kit for detecting free rare tumor cells in human biological fluid sample | |
| CN106370867B (en) | A kind of joint-detection assesses the kit of liver Transplantation for Hepatocellular Carcinoma recurrence and metastasis after resection risk | |
| CN104094116A (en) | Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject | |
| CN105115878A (en) | Circulating tumor cell detection kit, preparing method thereof and application thereof | |
| CN109187146B (en) | Human body cell full-form immunofluorescence staining method and kit | |
| CN107402296A (en) | The immunofluorescence dyeing and interpretation method of a kind of circulating tumor cell | |
| CN106980018B (en) | A kind of kit and its application using CD45 immunofluorescences joint CEP17 probe identification circulating tumor cells | |
| CN114127562A (en) | Detection method of tumor cell surface marker molecule PD-L1 | |
| CN106970225B (en) | A kind of kit and its application for combining 8 probe identification circulating tumor cells of CEP using CD45 immunofluorescences | |
| CN106970224B (en) | A kind of kit and its application using CD45 immunofluorescences joint CEP probe identification circulating tumor cells | |
| CN110095599B (en) | Micro-immunofluorescence detection method without cell loss | |
| CN110702589A (en) | Method for detecting exosome by flow cytometer | |
| CN108179134A (en) | Based on EpCAM/PSMA double antibody functionalization micro-flow control chips and its preparation method and application | |
| CN109439732A (en) | A kind of kit early sieved for three-dimensional noninvasive tumour | |
| CN111141906A (en) | Detection kit for peripheral blood circulating tumor cells and PD-L1 of small cell lung cancer patient | |
| CN104990905B (en) | A kind of hepatoma Metastasis diagnostic kit based on solid-phase enzyme-linked immune fluorescence spot | |
| CN102313813B (en) | Integration method for enriching and detecting rare cells from biological fluid samples | |
| CN112113821B (en) | Multiple staining slide preparation method of cytopathology sample | |
| CN209555255U (en) | A kind of kit early sieved for three-dimensional noninvasive tumour | |
| CN112113820A (en) | Staining and flaking method of cytopathology sample | |
| CN109439624A (en) | A method of for identification or enrichment erythroblast | |
| CN105087778A (en) | Method and related kit for detecting HER-2/CEP17 gene status based on rare cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |